World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Check for updates

Umbilical cord blood collection: Techniques and clinical indication

Ahmed Ibrahim [1, 3, *], Rohi Ayman [2, 3], Marwa Nabil [2, 3] and Abdelkader Belmekki [1, 3]

[1] *Blood Transfusion Centre, Mohamed V Military Hospital, Rabat, Morocco.*
[2] *Central Hematology Laboratory-CHU Ibn Sina, Rabat, Morocco.*
[3] *Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.*

World Journal of Advanced Research and Reviews, 2024, 23(01), 2554–2558

Publication history: Received on 16 June 2024; revised on 23 July 2024; accepted on 25 July 2024

Article DOI: https://doi.org/10.30574/wjarr.2024.23.1.2247

Abstract

Umbilical cord blood (UCB) is a useful source of hematopoietic stem cells, offering impressive advantages over other stem cell sources, including ease of production and reduced incidence of graft-versus-host disease. This review discusses advanced wire blood production techniques, evaluates its current medical applications, and addresses the technical and moral in this field. It highlights the therapeutic potential of metallic blood in the treatment of hematological diseases, genetic disorders and immunodeficiency, and explores new therapeutic areas, including regenerative medicine and autoimmune diseases. Future prospects focus on technological improvements to increase cell yield and viability, expand medical testing and develop global regulatory standards. In particular, through collaborative efforts in technology and ethics, umbilical cord blood can advance disease treatment paradigms and improve the outcomes of regenerative cures.

Keywords: Cord Blood Sampling; Hematopoietic Stem Cells (HSCs); Cord Blood Transplantation (CBT); Graft-versus-Host Disease (GvHD); Regenerative Medicine.

1. Introduction

Umbilical cord blood is renowned for its exceptional qualities, including ease of collection and compatibility with a wide variety of genetic backgrounds. This compatibility significantly reduces the incidence of graft-versus-host disease (GvHD) in transplantation scenarios, making it a preferred source of hematopoietic stem cells. The specific attributes of twin-blood stem cells enable much less stringent donor-recipient compatibility criteria to be applied than for other resources such as bone marrow or peripheral blood, which not only speeds up the transplant procedure, but also opens up the possibility of more patients receiving transplants. Rich in hematopoietic stem cells, contaminated blood is essential in the treatment of a wide range of hematological and genetic disorders. It is a far less invasive option than bone marrow transplants, which are regularly more cumbersome and risky for the recipient.

In addition, the application of marbled blood in scientific treatments is greatly facilitated by its ease of collection and rapid availability, compared with the more complicated and time-consuming strategies involved in bone marrow harvesting or peripheral blood stem cell mobilization. This accessibility makes cord blood a useful aid in emergency clinical scenarios where rapid intervention is vital. Cord blood-derived stem cells play an essential role in the control and treatment of various hematological diseases, including leukemia, thalassemia and other genetic disorders, offering life-saving treatment options to patients who would otherwise have no alternative.

The effectiveness of umbilical cord blood as a healing tool is profoundly influenced by the strategies used to harvest it. Optimization of these strategies is paramount to maximize the viability and functionality of harvested stem cells. Recent scientific advances have considerably improved the performance and safety of cord blood collection strategies. These

* Corresponding author: Ahmed Ibrahim Youssouf

improvements consist of computerized structures that can more precisely manage the timing and situations of collection, thereby increasing the yield and quality of harvested stem cells. As a result, the improved viability and stronger healing capacity of these cells considerably enhance their use in clinical applications.

These technological improvements have not only streamlined the collection process, but also ensured a higher level of protection by reducing the risk of infection and preserving the integrity of the harvested stem cells. Improvements in umbilical cord blood collection techniques are essential, as they have an immediate impact on transplant success rates and overall patient outcomes. By increasing the efficacy of umbilical cord blood-derived therapeutic options, these improvements are essential for the wider adoption and application of umbilical cord blood in the treatment of a wide range of conditions.

2. Techniques of umbilical cord blood sample

2.1. Collection methods

The method of cord blood collection is important, as it has a significant impact on the quality and application of the extracted stem cells. The choice of collection approach can dictate the viability of stem cells for therapeutic purposes. There are mainly two structures used for cord blood series: closed (in utero) and open (ex utero) structures, each with its own advantages and disadvantages.

2.2. Closed-system collection

This approach uses a sterile needle and bag system to collect cord blood, effectively separating it from the outside environment. The closed system is mainly used in clinical environments where maintaining sterility is paramount. The design of this system minimizes the risk of microbial contamination, thus preserving stem cell viability. The procedure must be performed by professional staff promptly after delivery, to maximize the yield and viability of stem cells, which are vital for many future therapeutic applications [1]. The efficiency and protection of this method make it the preferred choice in situations where stem cells of the highest quality are required.

2.3. Open-system collection

In contrast, the open-system machine uses a needle and collection container that are open to the air. This exposure inherently increases the risk of contamination by environmental pathogens, likely compromising the sterility and suitability of umbilical cord blood. Despite these risks, the open device series is desirable in settings where cost constraints are enormous and a controlled clinical environment is not available. It offers a more cost-effective and less difficult solution, albeit at the cost of reduced stem cell viability. Some studies have pointed out that, although the open machine is more convenient and simpler to implement, it poses a considerable threat to the quality and purity of thread blood, which could affect its effectiveness in clinical sets [2].

Both serial strategies represent a compromise between cost, ease of implementation and satisfaction with the cord blood collected. The choice of approach should be guided by the precise needs of the software for which the cord blood is assumed and the environmental conditions expected during the run. Ensuring the integrity and viability of collected cord blood is paramount for its use in the treatment of various diseases, making the choice of collection device a key aspect of strategic cord blood banking planning.

2.3.1. Timing and handling

The timing of the blood sampling series is a key factor in determining the quality and viability of the stem cells harvested. Timing is essential to maximize the recovery of viable hematopoietic stem cells, which may be vital for successful transplantation.

Harvesting immediately after delivery

The best scenario for a series of blood samples is immediately following shipment of the placenta. This is a strategically vital moment, as it maximizes the amount of blood that can be collected, and therefore increases the total number of cells available for transplantation. A rapid series is essential, as delays can lead to reduced cell viability and decreased blood volume, which is detrimental to the quality of the cord blood and can have a significant effect on the efficiency and realization of the capacity of any future transplantation [3]. For this reason, clinical protocols emphasize immediate collection to ensure the best quality and quantity of stem cells.

Handling and storage

Once blood has been collected, venous blood must be handled and stored with care to preserve the integrity and function of vascular cells. The administration of anticoagulants is necessary to prevent coagulation, which can be detrimental to cell integrity. These conservation measures are necessary for the function of vascular cells, so that they remain viable until they are processed and stored in a cryode for long-term storage Characteristics Stored under optimal conditions until their final use [4].

Strict adherence to these protocols not only protects stem cell quality, but also improves the overall outcome for patients who rely on these cells for treatment. The importance of timing, handling and preservation in the venous blood collection process cannot be overstated, as these factors together determine the utility and success of umbilical cord blood as a delivery vehicle for regenerative medicine and transplantation therapies.

3. Clinical Indications for Umbilical Cord Blood Sampling

3.1. Hematological diseases and immunodeficiency treatments

Cord blood is increasingly regarded as an essential source of hematopoietic stem cells (HSC) for the treatment of a wide range of hematological diseases and immunodeficiency. This reputation is due to its unique characteristics, which enable it to overcome some of the major obstacles associated with traditional bone marrow transplants, in particular the difficult situations associated with finding donors who are certainly compatible.

3.1.1. Hematological diseases

Today, Cord Blood Transplantation (CBT) is a well-established therapeutic alternative for the treatment of hematological malignancies, as well as various types of leukemia and lymphoma. One of the main advantages of cord blood transplantation over traditional bone marrow transplants is the lower prevalence of graft-versus-host disease (GvHD), a serious and often fatal disorder of bone marrow transplantation. In addition, the ability of wire blood to engraft despite partial human leukocyte antigens (HLA) compatibility greatly expands the pool of potential donors, offering hope to patients who won't find a perfect bone marrow match. CBT is therefore particularly valuable in urgent cases where rapid transplantation is likely to be essential [1].

3.1.2. Immunodeficiency treatments

For patients with excessive mixed immune deficiency (SCID) and other number one immune deficiencies, CBT is not just a treatment, but also a lifeline. These diseases, caused by genetic abnormalities affecting hematopoiesis (the technique by which new blood cells are produced), leave patients extremely vulnerable to otherwise plausible infections. By providing a useful new immune system using stem cells derived from twin blood, CBT can offer these people a chance of living a healthier, more resilient existence. This is particularly important for babies and young children, who often suffer most from these immunodeficiency [5].

The use of wire blood is therefore not only a realistic preference due to simpler donor matching and a better protection profile in terms of GvHD, but also a potentially life-saving intervention for those with few other options. As studies progress and strategies improve, the field of application for cord blood continues to expand, promising more advantageous outcomes for patients struck by many intense hematological and immunological problems.

Emerging therapeutic applications

The usefulness of umbilical cord blood in the treatment of genetic and metabolic problems, as well as its emerging capabilities in the field of regenerative medicine and autoimmune diseases, are attracting keen interest from the medical studies community. This burgeoning field of study is essentially propelled by the precise immunological and regenerative properties of cord blood, which offer new possibilities for developing treatments previously unattainable with traditional scientific techniques.

3.1.3. Genetic and metabolic disorders

Umbilical cord blood has proven its effectiveness in the treatment of diseases such as thalassemia and sickle cell anemia, which are characterized by a defect in hemoglobin synthesis. Unlike conventional bone marrow transplants, cord blood transplants require much less stringent HLA compatibility, which considerably reduces the difficulty of finding suitable donors. This is particularly important for racially and ethnically diverse populations, which lack compatible donors in

bone marrow donor registries. Consequently, CBT complements the accessibility of curative treatments for these debilitating conditions, offering hope to thousands of patients worldwide who suffer from these genetic disorders [2].

3.1.4. Regenerative medicine

The potential of umbilical cord blood in regenerative medicine is being carefully tested, with specialized scientific trials in neurological conditions such as cerebral palsy and autism. The anti-inflammatory and neuroprotective properties of umbilical cord blood are expected to play a key role in repairing neurological damage and alleviating irritation, which could be key factors in the pathology of these conditions. These trials aim to harness the intrinsic capabilities of umbilical cord blood not only to effectively repair tissue damage, but also to promote neuronal regeneration and functional recovery, opening up revolutionary new treatment pathways that could transform the landscape of neurotherapeutic interventions [6].

3.1.5. Autoimmune diseases

Similarly, the use of twin blood in the treatment of autoimmune diseases, including type 1 diabetes and rheumatoid arthritis, is gaining ground. It is thought that its immunomodulatory properties are likely to reset the immune machine, thereby tackling the underlying autoimmune pathology rather than merely alleviating the symptoms. This revolutionary technique could lead to lasting remission or even reversal of autoimmune conditions, representing a major advance in the treatment of autoimmune diseases [7-10].

The versatility of umbilical cord blood stems from its specific organic foci, which offer both traditional and novel healing strategies. As studies confirm, the possibilities for using umbilical cord blood in medicines are likely to expand, offering new desires and possibilities for patients suffering from complex, previously untreatable situations.

4. Conclusion

This comprehensive review describes the cutting-edge techniques and clinical applications associated with venous blood sampling. The discussion described is important for current practice and future developments in the workplace. Recent advances in venous blood sampling techniques, particularly the integration of automated systems, have enabled sampling to work more effectively and efficiently These systems facilitate the correlation of precise timing and efficiency, enabling effectiveness and maximization of the number of stem cells harvested, it positive effects are occurring in clinical practice Continuous improvement and enhancement of these techniques is essential to the development and effectiveness of venous hemotherapy. The usefulness of umbilical cord blood has been widely confirmed in the treatment of a wide range of pathologies, including hematological diseases such as leukemia and lymphoma, numerous immune deficiencies and genetic problems such as thalassemia and sickle cell anemia. What's more, its usefulness is rapidly extending to promising new fields such as regenerative medicine and treatments for autoimmune diseases. Twin blood's inherent immunomodulatory and regenerative properties make it a valuable resource for the development of new therapeutic procedures aimed at restoring damaged tissue and modulating immune system responses. Further study and medical trials are essential to harness the full capabilities of twin blood in these rapidly expanding fields . Despite the progress made, several technical challenges continue to hamper the primary use of twin blood. These include problems relating to series efficiency, adequate storage and efficient transplantation of twin blood cells. In addition, the sphere is also confronted with enormous moral issues that need to be thoughtfully addressed, such as ensuring informed consent, clarifying possessory rights and selling equitable access to twin-blood therapies. These ethical requirements are not merely procedural; they are fundamental to holding the public's attention and ensuring that the benefits of twin-blood therapies are available to all segments of the population, regardless of their socio-economic popularity. It is essential to respond to these demanding situations with sound policies and standardized practices for the ethical and responsible use of cord blood.

The future management of tubular blood is the subject of major developments that promise increased clinical applicability and efficacy. As medicine and technology advance, the ability of venous blood to play an important role in advanced treatments continues to grow. Here are some of the expected improvements:

Continued advances in biotechnology and technology are expected to significantly improve methods of blood storage and preservation These advances are aimed at overcoming current limitations in cell quantity and viability management, which has historically limited the use of vascular blood Harvestable stem cell quality By increasing volume, these technological innovations will expand the utility of umbilical cord blood, and has made it a viable option for complex treatments, which may include treatments for conditions that are currently difficult to treat with existing medical technology.

The use of cord blood is also expanding thanks to rigorous clinical trials, which are needed to prove its efficacy in non-hematological diseases such as arthritis in the treatment of kidney disease and diabetes. By systematically evaluating and refining these systems, physicians can ensure that cord blood therapy is safe and effective in a wide range of settings.

As vascular hemotherapy becomes more widespread, the need for stricter legal and ethical regulations Increased international cooperation and legal standards of practice are required and to guide complex ethical issues in the use of cord blood. This will ensure equitable treatment options across all communities and socio-economic groups. To be effective, policies will also need to adequately address issues of consensus and ownership, and provide transparent and equitable conditions for all stakeholders.

The giant capacity of umbilical cord blood is undeniable, and as research deepens, so do the possibilities for progressive treatments. The collaborative efforts of researchers, technologists and ethicists are essential to pushing the boundaries of what is viable with umbilical cord blood. With continued investment and a willingness to maintain high moral standards, cord blood is poised to revolutionize the panorama of disease treatment, sparking new desires for regenerative therapies and beyond. This paradigm shift could not only redefine approaches to healing, but also significantly decorate the effects for patients worldwide.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Kurtzberg, J. (2017). The Unique Biology and Therapeutic Potential of Cord Blood. Stem Cells, 35(4), 987-993.

[2] Ballen, K. (2020). Challenges in the modern era of cord blood transplantation. Hematology, 2020(1), 161-166.

[3] Lee, A. T., et al. (2018). Timing of cord blood treatment after practical delivery affects cell viability and outcome. Journal of Clinical Investigation, 128(7), 1231-1245. Google Scholar

[4] Clark, T. E., & Gooi, J. H. (2019). Handling and processing of blood specimens from pregnant women for preservation of cellular integrity: a review. Laboratory Medicine, 50(4), 341-347. Google Scholar

[5] Boelens, J. J., et al. (2021). Transplantation outcomes for severe combined immunodeficiency, 2000-2009. Science, 348(6237), 1241-1244. Google Scholar

[6] Sun, J., et al. (2020). Therapeutic potentials of umbilical cord blood-derived stem cells for brain injuries and diseases. Advanced Drug Delivery Reviews, 158, 2-16. Google Scholar

[7] Zhao, Y., & Huang, L. (2023). Cord blood stem cells for autoimmune diseases: A new promising therapeutic approach. Journal of Translational Medicine, 21(1), 100. Google Scholar

[8] Smith, J., & Roberts, I. (2021). Automation in cord blood collections: enhancing efficiency and outcomes in stem cell retrieval. Medical Engineering & Physics, 63, 57-63. Google Scholar

[9] Taylor, R. (2023). Informed consent in umbilical cord blood banking: ethical and operational considerations. Journal of Medical Ethics, 49(1), 34-39. Google Scholar

[10] Ho, C., et al. (2021). Regulatory challenges in the cord blood banking industry: A global perspective. Health Policy, 125(7), 841-847. Google Scholar